PRESS RELEASES

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Nov 15, 2022, 07:30 ET ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a…

Read more

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Oct 18, 2022, 07:30 ET Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced…

Read more

Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment

Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment Over-subscribed round to support Phase2a clinical trial in atopic dermatitis ANNAPOLIS, MD, September 15, 2022 – Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3…

Read more

NEWS, EVENTS, PRESENTATIONS

CEO and Chairman of Alphyn Biologics talks with CONNECTpreneur Anchor and Phoenix Fund General Partner

Neal Koller, CEO and Chairman of Alphyn Biologics, talks with Laura Hill, CONNECTpreneur Anchor and Phoenix Fund General Partner in Tysons Corner, Virginia in February, 2020 Alphyn is a life science company developing proprietary drug therapy for treating serious skin diseases. The initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based…

Read more

BIO International 2019

BIO International 2019 Alphyn was selected to present at BIO International 2019 on June 6, 2019, in Philadelphia, Pennsylvania.  Chairman & CEO Neal Koller presented.

Read more